Viemed Healthcare (NASDAQ: VMD) insider transactions
In the twelve months to 10 November 2026, executives and directors of Viemed Healthcare reported 9 open-market sales of 166,802 shares ($1.6m) and 0 open-market purchases, by 3 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 19 August 2026 | Dobbs Randy E. | Director | Option exercise | +16,763 | — | 142,253 | Form 4 |
| 19 August 2026 | Dobbs Randy E. | Director | Option exercise | +4,191 | — | 146,444 | Form 4 |
| 19 August 2026 | Dobbs Randy E. | Director | Returned to the company | −4,191 | $8.94 | 142,253 | Form 4 |
| 19 August 2026 | Smokoff Timothy | Director | Option exercise | +15,029 | — | 90,547 | Form 4 |
| 19 August 2026 | Smokoff Timothy | Director | Option exercise | +3,757 | — | 94,304 | Form 4 |
| 19 August 2026 | Smokoff Timothy | Director | Returned to the company | −3,757 | $8.94 | 90,547 | Form 4 |
| 19 August 2026 | Kaushal Nitin | Director | Option exercise | +18,786 | — | 161,361 | Form 4 |
| 19 August 2026 | Heltz Sabrina | Director | Option exercise | +15,029 | — | 82,520 | Form 4 |
| 19 August 2026 | Heltz Sabrina | Director | Option exercise | +3,757 | — | 86,277 | Form 4 |
| 19 August 2026 | Heltz Sabrina | Director | Returned to the company | −3,757 | $8.94 | 82,520 | Form 4 |
| 25 June 2026 | Frazier William | Chief Medical Officer | Option exercise | +10,000 | $1.81 | 83,214 | Form 4 |
| 25 June 2026 | Frazier William | Chief Medical Officer | Open-market sale | −10,000 | $11.72 | 73,214 | Form 4 |
| 24 June 2026 | Smokoff Timothy | Director | Open-market sale | −1,636 | $11.48 | 93,882 | Form 4 |
| 24 June 2026 | Smokoff Timothy | Director | Open-market sale | −3,364 | $11.50 | 90,518 | Form 4 |
| 24 June 2026 | Smokoff Timothy | Director | Open-market sale | −5,000 | $11.56 | 85,518 | Form 4 |
| 24 June 2026 | Smokoff Timothy | Director | Open-market sale | −5,000 | $11.53 | 80,518 | Form 4 |
| 24 June 2026 | Smokoff Timothy | Director | Open-market sale | −5,000 | $11.41 | 75,518 | Form 4 |
| 20 March 2026 | Moore Michael | President | Open-market sale | −65,000 | $8.77 | 1,585,812 | Form 4 |
| 19 March 2026 | Moore Michael | President | Open-market sale | −40,232 | $9.21 | 1,650,812 | Form 4 |
| 18 March 2026 | Moore Michael | President | Open-market sale | −31,570 | $9.42 | 1,691,044 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Viemed Healthcare page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.